Next 10 |
2024-06-28 13:53:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Oragenics (NYSEMKT: OGEN ) just reported results for the fourth quarter of 2023. Oragenics reported earnings per share of -$5.48. The company did not report any revenu...
2024-06-27 08:59:56 ET More on Oragenics Oragenics prices public offering of common stock Oragenics climbs 9% amid Phase 2 study, business updates Financial information for Oragenics Read the full article on Seeking Alpha For further details see: ...
SARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has completed a prototype of its automated intranasal device for use in concu...
SARASOTA, Fla., June 26, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the closing of its public offering of 1,100,000 shares of its common stock ...
A look at the top 10 most actives in the United States GlycoMimetics Inc. (GLYC) rose 42.5% to $0.38 on volume of 73,016,681 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.16 on volume of 71,818,174 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 25.4% to $0.2431 on volume...
2024-06-25 09:43:24 ET More on Oragenics Oragenics climbs 9% amid Phase 2 study, business updates Oragenics files 10K and provides company update Financial information for Oragenics Read the full article on Seeking Alpha For further details see: O...
SARASOTA, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and ...
2024-06-25 01:52:34 ET More on Oragenics Oragenics climbs 9% amid Phase 2 study, business updates Oragenics files 10K and provides company update Financial information for Oragenics Read the full article on Seeking Alpha For further details see: O...
SARASOTA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it intends to offer and s...
SARASOTA, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the “Notice”) from the NYSE American LL...
News, Short Squeeze, Breakout and More Instantly...
SARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has completed a prototype of its automated intranasal device for use in concu...
SARASOTA, Fla., June 26, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the closing of its public offering of 1,100,000 shares of its common stock ...